RU2375363C2 - Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы - Google Patents
Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы Download PDFInfo
- Publication number
- RU2375363C2 RU2375363C2 RU2004134337/04A RU2004134337A RU2375363C2 RU 2375363 C2 RU2375363 C2 RU 2375363C2 RU 2004134337/04 A RU2004134337/04 A RU 2004134337/04A RU 2004134337 A RU2004134337 A RU 2004134337A RU 2375363 C2 RU2375363 C2 RU 2375363C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- phenyl
- substituted
- atom
- atoms
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- UBWMDGGQTGIGMI-UHFFFAOYSA-N NC1=CC=CC=C1.N1N=NC=C2N=CC=C21 Chemical class NC1=CC=CC=C1.N1N=NC=C2N=CC=C21 UBWMDGGQTGIGMI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 24
- 150000003839 salts Chemical class 0.000 claims abstract 22
- 239000012453 solvate Substances 0.000 claims abstract 18
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 104
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 53
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 46
- 125000000623 heterocyclic group Chemical group 0.000 claims 35
- 125000005842 heteroatom Chemical group 0.000 claims 29
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical class 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 7
- 125000002757 morpholinyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
- 229930194542 Keto Natural products 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000000468 ketone group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 1
- -1 pyrimidinyl pyrazinyl Chemical group 0.000 claims 1
- 150000003921 pyrrolotriazines Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 CCCNC(c(c(C)c12)c[n]1ncnc2Nc1cc(C(NC(C=CO)=*)=O)ccc1C)=O Chemical compound CCCNC(c(c(C)c12)c[n]1ncnc2Nc1cc(C(NC(C=CO)=*)=O)ccc1C)=O 0.000 description 1
- GWCFQFRVXVHDEC-AWEZNQCLSA-N CC[C@H](C)NC(c(c(C)c12)c[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C)=O Chemical compound CC[C@H](C)NC(c(c(C)c12)c[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C)=O GWCFQFRVXVHDEC-AWEZNQCLSA-N 0.000 description 1
- PDFIVWAFBNUBFL-UHFFFAOYSA-N Cc(c(C(NCc1cnccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C Chemical compound Cc(c(C(NCc1cnccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C PDFIVWAFBNUBFL-UHFFFAOYSA-N 0.000 description 1
- MHTTVYQQRUEVHY-UHFFFAOYSA-N Cc(c(C(NCc1ncccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C Chemical compound Cc(c(C(NCc1ncccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C MHTTVYQQRUEVHY-UHFFFAOYSA-N 0.000 description 1
- REOZTDSFTFSXFY-UHFFFAOYSA-N Cc(c(C(NCc1ncccc1F)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C Chemical compound Cc(c(C(NCc1ncccc1F)=O)c1)c2[n]1ncnc2Nc1cc(C(NC2CC2)=O)ccc1C REOZTDSFTFSXFY-UHFFFAOYSA-N 0.000 description 1
- AQIOJZLQOCMJRZ-UHFFFAOYSA-N Cc(c(C(c1ccccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC)=O)ccc1C Chemical compound Cc(c(C(c1ccccc1)=O)c1)c2[n]1ncnc2Nc1cc(C(NC)=O)ccc1C AQIOJZLQOCMJRZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37493802P | 2002-04-23 | 2002-04-23 | |
| US60/374,938 | 2002-04-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004134337A RU2004134337A (ru) | 2005-06-27 |
| RU2375363C2 true RU2375363C2 (ru) | 2009-12-10 |
Family
ID=29270573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004134337/04A RU2375363C2 (ru) | 2002-04-23 | 2003-04-15 | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US7160883B2 (enExample) |
| EP (2) | EP2289894A3 (enExample) |
| JP (2) | JP4669225B2 (enExample) |
| KR (1) | KR101025675B1 (enExample) |
| CN (2) | CN102093363B (enExample) |
| AR (1) | AR039649A1 (enExample) |
| AU (1) | AU2003231034B2 (enExample) |
| BR (1) | BR0309669A (enExample) |
| CA (1) | CA2483164C (enExample) |
| DK (1) | DK1497019T3 (enExample) |
| ES (1) | ES2543711T3 (enExample) |
| GE (1) | GEP20074148B (enExample) |
| HR (1) | HRP20040988A2 (enExample) |
| HU (1) | HUE025353T2 (enExample) |
| IL (2) | IL164573A (enExample) |
| IS (1) | IS7505A (enExample) |
| MX (1) | MXPA04010379A (enExample) |
| MY (1) | MY132094A (enExample) |
| NO (1) | NO329503B1 (enExample) |
| NZ (1) | NZ536014A (enExample) |
| PE (1) | PE20040590A1 (enExample) |
| PL (1) | PL219736B1 (enExample) |
| PT (1) | PT1497019E (enExample) |
| RS (1) | RS92004A (enExample) |
| RU (1) | RU2375363C2 (enExample) |
| SI (1) | SI1497019T1 (enExample) |
| TW (1) | TWI312782B (enExample) |
| UA (1) | UA78562C2 (enExample) |
| WO (1) | WO2003090912A1 (enExample) |
| ZA (1) | ZA200408541B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| HRP20040988A2 (en) * | 2002-04-23 | 2005-06-30 | Bristol-Myers Squibb Company A Delaware (Usa) Corp | Pyrrolo-triazine aniline compounds useful as kinas |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| MXPA05008183A (es) * | 2003-02-05 | 2005-10-05 | Bristol Myers Squibb Co | Proceso para preparar pirrolotriazina como inhibidores de cinasa. |
| US20060281803A1 (en) * | 2003-09-23 | 2006-12-14 | Lindsley Craig W | Pyrazole modulators of metabotropic glutamate receptors |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2005058832A1 (en) * | 2003-12-10 | 2005-06-30 | Merck Patent Gmbh | Diacylhydrazine derivatives |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| ES2339670T3 (es) * | 2003-12-23 | 2010-05-24 | Novartis Ag | Inhibidores heterociclicos biciclicos de la quinasa p-38. |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| US7148348B2 (en) | 2004-08-12 | 2006-12-12 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| CN101035791B (zh) * | 2004-10-26 | 2010-12-08 | 诺瓦提斯公司 | 作为c-JUN N末端激酶（JNK）和P-38激酶的抑制剂的吡咯并[1,2-D][1,2,4]三嗪 |
| US7534882B2 (en) | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| EA200801945A1 (ru) | 2006-03-07 | 2009-02-27 | Бристол-Маерс Сквибб Компани | Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| JP5180967B2 (ja) * | 2006-11-03 | 2013-04-10 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
| CN103237795B (zh) | 2010-09-24 | 2015-10-21 | 百时美施贵宝公司 | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 |
| CN103848833B (zh) * | 2012-11-28 | 2016-08-31 | 上海希迈医药科技有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用 |
| WO2014082230A1 (zh) * | 2012-11-28 | 2014-06-05 | 上海希迈医药科技有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用 |
| EP2948454B1 (en) | 2013-01-24 | 2017-05-31 | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) | Triazine compounds and a process for preparation thereof |
| CN103601722B (zh) * | 2013-09-13 | 2016-03-02 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
| ES2678877T3 (es) | 2013-10-11 | 2018-08-20 | Bristol-Myers Squibb Company | Inhibidores de pirrolotriazina quinasa |
| ES2683127T3 (es) | 2013-10-17 | 2018-09-25 | Blueprint Medicines Corporation | Composiciones útiles para tratar trastornos relacionados con la KIT |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| EP3566054A4 (en) * | 2017-01-05 | 2020-12-09 | Biodesix, Inc. | PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| AU2020272743B2 (en) | 2019-04-12 | 2025-10-16 | Blueprint Medicines Corporation | Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases |
| LT3856341T (lt) | 2019-04-12 | 2023-12-27 | Blueprint Medicines Corporation | (s)-1-(4-fluorfenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f] [1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amino kristalinės formos ir gamybos būdai |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN110483497B (zh) * | 2019-08-28 | 2022-12-30 | 郑州手性药物研究院有限公司 | 6-氨基甲基-1,1-二氧-1,2-苯并噻唑-3-酮中间体及其合成方法 |
| CN110627706B (zh) * | 2019-08-28 | 2023-02-10 | 郑州手性药物研究院有限公司 | 2-(4-甲基苄基)-1h-异吲哚-1,3-二酮衍生物及其合成方法 |
| CN110483439B (zh) * | 2019-08-28 | 2022-12-30 | 郑州手性药物研究院有限公司 | 6-氨基甲基-1,1-二氧-1,2-苯并噻唑-3-酮的合成方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2127274C1 (ru) * | 1992-09-25 | 1999-03-10 | Эли Лилли Энд Компани | СПОСОБ ПОЛУЧЕНИЯ 5-ЗАМЕЩЕННЫХ ПИРРОЛО (2,3-α)ПИРИМИДИНОВ |
| WO2000021563A1 (en) * | 1998-10-14 | 2000-04-20 | Shionogi & Co., Ltd. | Remedies or preventives for ischemic reflow failure |
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| WO2001014378A1 (en) * | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629301A (en) | 1969-10-24 | 1971-12-21 | Du Pont | 3 3-difluoro-2-substituted steroids and their preparation |
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
| US5977103A (en) | 1996-01-11 | 1999-11-02 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
| US6251914B1 (en) | 1997-07-02 | 2001-06-26 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| BR9913654A (pt) | 1998-08-28 | 2001-11-27 | Scios Inc | Inibidores de p-38alfa quinase |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| CA2337755C (en) * | 1998-09-18 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| BR9914162A (pt) | 1998-10-01 | 2001-06-26 | Astrazeneca Ab | Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| KR20010089805A (ko) | 1999-11-10 | 2001-10-08 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 치환된 2-아릴-3-(헤테로아릴)-이미다조[1,2-ａ]피리미딘,및 관련 약제학적 조성물 및 방법 |
| US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| GEP20063915B (en) * | 2000-11-17 | 2006-09-11 | Bristol Myers Squibb Co | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS |
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| JP4510442B2 (ja) * | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| HRP20040988A2 (en) * | 2002-04-23 | 2005-06-30 | Bristol-Myers Squibb Company A Delaware (Usa) Corp | Pyrrolo-triazine aniline compounds useful as kinas |
| ATE418546T1 (de) * | 2002-04-23 | 2009-01-15 | Bristol Myers Squibb Co | Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen |
| TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TWI272271B (en) * | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| MXPA05008183A (es) * | 2003-02-05 | 2005-10-05 | Bristol Myers Squibb Co | Proceso para preparar pirrolotriazina como inhibidores de cinasa. |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| US7534882B2 (en) * | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| EA200801945A1 (ru) * | 2006-03-07 | 2009-02-27 | Бристол-Маерс Сквибб Компани | Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы |
-
2003
- 2003-04-15 HR HR20040988A patent/HRP20040988A2/hr not_active Application Discontinuation
- 2003-04-15 CA CA2483164A patent/CA2483164C/en not_active Expired - Fee Related
- 2003-04-15 EP EP10178247A patent/EP2289894A3/en not_active Withdrawn
- 2003-04-15 WO PCT/US2003/012426 patent/WO2003090912A1/en not_active Ceased
- 2003-04-15 ES ES03724157.7T patent/ES2543711T3/es not_active Expired - Lifetime
- 2003-04-15 GE GEAP8506A patent/GEP20074148B/en unknown
- 2003-04-15 RU RU2004134337/04A patent/RU2375363C2/ru not_active IP Right Cessation
- 2003-04-15 JP JP2003587532A patent/JP4669225B2/ja not_active Expired - Fee Related
- 2003-04-15 NZ NZ536014A patent/NZ536014A/en not_active IP Right Cessation
- 2003-04-15 DK DK03724157.7T patent/DK1497019T3/en active
- 2003-04-15 RS YU92004A patent/RS92004A/sr unknown
- 2003-04-15 PT PT37241577T patent/PT1497019E/pt unknown
- 2003-04-15 CN CN201010616344.7A patent/CN102093363B/zh not_active Expired - Fee Related
- 2003-04-15 SI SI200332435T patent/SI1497019T1/sl unknown
- 2003-04-15 AU AU2003231034A patent/AU2003231034B2/en not_active Ceased
- 2003-04-15 CN CN038142937A patent/CN1662509A/zh active Pending
- 2003-04-15 PL PL373338A patent/PL219736B1/pl unknown
- 2003-04-15 MX MXPA04010379A patent/MXPA04010379A/es active IP Right Grant
- 2003-04-15 KR KR1020047017020A patent/KR101025675B1/ko not_active Expired - Fee Related
- 2003-04-15 HU HUE03724157A patent/HUE025353T2/en unknown
- 2003-04-15 UA UA20041109628A patent/UA78562C2/uk unknown
- 2003-04-15 EP EP20030724157 patent/EP1497019B1/en not_active Expired - Lifetime
- 2003-04-15 BR BR0309669-6A patent/BR0309669A/pt not_active Application Discontinuation
- 2003-04-18 TW TW092109121A patent/TWI312782B/zh not_active IP Right Cessation
- 2003-04-22 MY MYPI20031516A patent/MY132094A/en unknown
- 2003-04-22 US US10/420,399 patent/US7160883B2/en not_active Expired - Lifetime
- 2003-04-23 AR ARP030101401A patent/AR039649A1/es not_active Application Discontinuation
- 2003-04-23 PE PE2003000402A patent/PE20040590A1/es not_active Application Discontinuation
-
2004
- 2004-10-14 IS IS7505A patent/IS7505A/is unknown
- 2004-10-14 IL IL164573A patent/IL164573A/en not_active IP Right Cessation
- 2004-10-21 ZA ZA2004/08541A patent/ZA200408541B/en unknown
- 2004-10-22 NO NO20044560A patent/NO329503B1/no not_active IP Right Cessation
-
2006
- 2006-10-24 US US11/585,598 patent/US7462616B2/en not_active Expired - Lifetime
-
2007
- 2007-08-30 IL IL185604A patent/IL185604A0/en unknown
-
2008
- 2008-10-28 US US12/259,483 patent/US7759343B2/en not_active Expired - Lifetime
-
2010
- 2010-01-15 JP JP2010007097A patent/JP5226018B2/ja not_active Expired - Fee Related
- 2010-06-03 US US12/793,016 patent/US20100240646A1/en not_active Abandoned
- 2010-12-31 US US12/983,048 patent/US20110098467A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2127274C1 (ru) * | 1992-09-25 | 1999-03-10 | Эли Лилли Энд Компани | СПОСОБ ПОЛУЧЕНИЯ 5-ЗАМЕЩЕННЫХ ПИРРОЛО (2,3-α)ПИРИМИДИНОВ |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| WO2000021563A1 (en) * | 1998-10-14 | 2000-04-20 | Shionogi & Co., Ltd. | Remedies or preventives for ischemic reflow failure |
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2001014378A1 (en) * | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2375363C2 (ru) | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы | |
| RU2353616C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| US10023591B2 (en) | Heterocyclic derivatives and use thereof | |
| RU2404979C2 (ru) | 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ | |
| AU2015335694B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| RU2005122484A (ru) | Композиции, используемые в качестве ингибиторов протеинкиназ | |
| RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
| RU2004121161A (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и их применение | |
| RU2003115429A (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| JP2016536364A5 (enExample) | ||
| JP2016536363A5 (enExample) | ||
| RU2008125196A (ru) | Новые производные тиофена | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| JP2002543185A5 (enExample) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2007501831A5 (enExample) | ||
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов | |
| NO20063330L (no) | Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer | |
| NZ228722A (en) | Substituted indole and indazole derivatives and pharmaceutical compositions | |
| RU2006129164A (ru) | Цианопиримидиноны | |
| RU2008115499A (ru) | Новые производные аминокиламидов в качестве антагонистов лигандов рецепторов ccr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190416 |